Obesity Leadership Edge: A PA-Driven Chronic Care Model for the Management of Overweight and Obesity | Module 5: Pharmacologic Therapy
This interactive module is five of seven designed to prepare PAs to effectively care for patients affected by obesity.

A PA-Driven Chronic Care Model for the Management of Overweight and Obesity | Module 5: Pharmacologic Therapy

Karlijn Burridge, PA-C; Ji Chun, PA-C, MPAS, BC-ADM; Lawrence Herman, MPA, PA-C, DFAAPA; Amy Ingersoll, PA-C, MMS; Nancy McLaughlin, PA-C; Corri Wolf, PA-C, RD

Obesity is a chronic disease that results in multiple complications and yet is rarely addressed in a systematic way in health care. This module provides an overview of the guidelines for pharmacotherapy eligibility and explores medications available for weight loss, as well as medications associated with weight gain.

Educational Objectives

At the conclusion of this activity, you should be able to:
  • Determine which patients are eligible for anti-obesity medications.
  • Describe the FDA-approved medications for weight loss, including mechanism of action, efficacy, indication, and contraindications.
  • Review medications that are used off-label for weight loss and appraise the evidence that may support their use.
  • Assess current medications to identify drugs that are associated with weight gain and consider alternatives.
  • Select appropriate weight loss medications for eligible patients, and prescribe and monitor therapy.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credit by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval valid until June 30, 2020.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Program Developers

Karlijn Burridge, PA-C
Buffington Medical Weight Loss
Keller, TX
No commercial relationships to disclose

Laguna Nigel, CA
Disclosures: Received honorarium for Advisory Board for GSK, AstraZeneca, and Sanofi

Lawrence Herman, MPA, PA-C, DFAAPA
Gardner-Webb University, College of Health Sciences
Bolling Springs, NC
Disclosures: Served as consultant and member of the Novo Nordisk Speaker’s Bureau for obesity

Amy Ingersoll, PA-C, MMS
Arizona Health + Wellness
Phoenix, AZ
Disclosures: Novo Nordisk and Saxenda Speakers Bureaus

Nancy McLaughlin, PA-C
Roswell, GA
No commercial relationships to disclose 

Corri Wolf, PA-C, RD
New York Institute of Technology
Old Westbury, NY
No commercial relationships to disclose

Activity Planners

Marie-Michele Leger, MPH, PA-C
Alexandria, VA
Employment - AAPA

Eric Peterson
Alexandria, VA
Employment - AAPA

Off-Label/Unapproved Product(s) Discussion

There are no references to off-label/unapproved uses of products in this program. 


The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Acknowledgement of Commercial Support

Supported by an educational grant from Novo Nordisk

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.

Type:     Internet Activity (Enduring Material)
1564 Registered Users